e-learning
resources
ERJ
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension
Ghofrani H.A., Friese G., Discher T., Olschewski H., Schermuly R.T., Weissmann N., Seeger W., Grimminger F., Lohmeyer J.
Source:
Eur Respir J 2004; 23: 321-326
Journal Issue:
February
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ghofrani H.A., Friese G., Discher T., Olschewski H., Schermuly R.T., Weissmann N., Seeger W., Grimminger F., Lohmeyer J.. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23: 321-326
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001
Inhaled iloprost reverses chronic experimental pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 353s
Year: 2005
The burden of pulmonary hypertension
Source: Annual Congress 2006 - The burden of pulmonary hypertension
Year: 2006
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 339-343
Year: 2002
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Inhaled iloprost for the treatment of pulmonary hypertension
Source: Eur Respir Rev 2009; 18: 29-34
Year: 2009
Long-term effects of bosentan in patients with human immunodeficiency virus-associated pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary vascular medicine
Year: 2008
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006
Inhaled iloprost in HIV-related pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 24s
Year: 2002
Pulmonary arterial hypertension in patients with HIV infection
Source: Eur Respir Mon 2012; 57: 82-93
Year: 2012
Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: 563-567
Year: 2006
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Pulmonary hypertension: future therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84
Year: 2004
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids
Source: Eur Respir J 2003; 22: 330-334
Year: 2003
Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept